Furthermore, we determined that KV enlargement is rescued by the injection of Xenopus pkd2 mRNA and by 100 μM tolvaptan treatment, the unique and approved pharmacologic approach for ADPKD management. This evidence concerns the gene PKD2 and autosomal dominant polycystic kidney disease.